Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2023 - 01 - 18 tags : Drug save search
Pharmascience Canada launched (PR)pms-DEFERASIROX (TYPE J), a generic drug indicated in the management of chronic iron
Published: 2023-01-18 (Crawled : 19:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.93%
H: 0.01%
C: -1.16%
management drug canada
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of SarcoidosisGlobal pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis launched in Europe
Published: 2023-01-18 (Crawled : 18:00) - biospace.com/
LIFE | $1.6 -1.23% -1.25% 160K
|
Health Technology
|
| O: 0.0%
H: 2.45%
C: -2.18%
treatment europe designation drug grants study
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
Published: 2023-01-18 (Crawled : 15:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 1.32%
H: 4.49%
C: 1.01%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.36%
H: 0.33%
C: -1.13%
orpathys drug agreement china
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.5%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.4%
H: 0.75%
C: -1.21%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.21%
H: 1.66%
C: 1.46%
drug tyvyt china
Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
PEAR | $0.0292 -38.91% -59.33% 66M
|
Professional, Scientific, and T...
|
| O: 5.83%
H: 0.0%
C: -10.24%
reset drug therapeutics
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Published: 2023-01-18 (Crawled : 13:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 1.82%
H: 0.74%
C: -4.85%
qinlock drug
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
Published: 2023-01-18 (Crawled : 12:20) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: 1.82%
H: 0.74%
C: -4.85%
PRTK | $2.23 0.0% 4.8M
|
Health Technology
|
| O: 2.16%
H: 3.38%
C: -10.13%
nuzyra pharmaceuticals drug
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.